In the treatment of cSCC, research has predominantly focused on EGFR/CD3 bispecific antibodys, with additional investigations exploring other targets such as PD-L1/CD3 and EpCAM/CD3. This evidence concerns the gene EGFR and skin squamous cell carcinoma.